Skip to content

Ketamine Enhances Analgesia and Mood in Chronic Pain Patients

Ketamine Analgesia Enhances Functional Quality and Mood in Chronic Pain Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05985811
Enrollment
500
Registered
2023-08-14
Start date
2018-02-02
Completion date
2025-12-31
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mood Disorder; Opioid, Mood Insomnia

Keywords

Mood therapy

Brief summary

Most chronic pain patients have mood disorders. The mood disorders may improve with better analgesia produced by Ketamine injections. A prospective study of patients undergoing interventional pain therapy using Ketamine injections. Pre-injection and post-injection patient data is collected. Pain is measured using numeric pain rating scale, and change in pain score by 2-points is considered significant. Sleep is measured using Likert sleep scale, and change in sleep score by 2-points is considered significant. Anxiety is measured using general anxiety disorder (GAD-7) scale, and change in anxiety score by 4-points is considered significant. Depression is measured using patient health questionnaire (PHQ-9), and change in depression score by 5-points is considered significant.

Detailed description

Chronic pain is usually associated with psychological and mood disorders. Many chronic pain patients have various forms of mood abnormalities; and these mood issues may improve with better analgesia produced by Ketamine injections. This is a prospective observational study of consenting adult patients who are undergoing interventional pain management. The patients undergo routine interventional pain therapy using Ketamine injections. Pre-injection and post-injection patient data is collected using validated tools. Data collection includes patients' age, psychiatric diagnosis, pain score, sleep score, anxiety score and depression score. Pain score is measured using the numeric pain rating scale, and a change in the pain score by 2-points is considered significant. Sleep score is measured using the Likert sleep scale, and a change in the sleep score by 2-points is considered significant. Anxiety is measured using the general anxiety disorder (GAD-7) scale, and a change in the anxiety score by 4-points is considered significant. Depression is measured using the patient health questionnaire (PHQ-9) scale, and a change in the depression score by 5-points is considered significant. Data is analyzed with IBM® SPSS® Statistics 25; using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value \<0.05 is considered significant.

Interventions

None listed

Sponsors

Salem Anaesthesia Pain Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* adult chronic pain patients * associated mood disorder * good treatment compliance * associated chronic insomnia * regular ketamine pain therapy injection * consent for clinical record quality assurance review

Exclusion criteria

* severe cognitive disorder * inability to provide consent * major neuropsychiatric disorder * cannabis use * stimulant use * substance abuse * poor treatment compliance * lack of ketamine pain therapy injection

Design outcomes

Primary

MeasureTime frameDescription
Pain score, objective measurement using the validated Numeric Pain Rating scale12 weeksPain score, using the Numeric Pain Rating scale of 0 to 10, low scores indicate less pain, high scores indicate worse pain

Secondary

MeasureTime frameDescription
Sleep quality score, objective measurement using the validated Likert sleep scale12 weeksSleep quality score, using the Likert sleep scale of 0 to 10, low scores indicate poor sleep, high scores indicate better sleep

Countries

Canada

Contacts

Primary ContactOlumuyiwa Bamgbade, MD,FRCPC
salem.painclinic@gmail.com17786286600
Backup ContactOlu Bamgbade, MD,FRCPC
olu.bamgbade@gmail.com17786286600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026